ScholarLens Back to search
2021•Multiple Sclerosis and Related DisordersOpen access

Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis

Kelly R. Cotchett, Bonnie N. Dittel, Ahmed Z. Obeidat

Open full text 74 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 74 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ocrelizumab, Ofatumumab, Medicine, Teriflunomide, Clinical trial, Multiple sclerosis, Adverse effect, Phases of clinical research

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis — Research Paper | ScholarLens